Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in Advanced Cervical Cancer
NCT01613677Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in Cervical Cancer (CC), sponsored by Novartis. Planned start Nov 2015; status: withdrawn.
02
Drugs
buparlisib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01613677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613677.